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1.  Purinergic receptor classification and functions in physiological 
conditions
One of the most abundant molecules in living cells serving as an intracellular 
energy source is adenosine-5′-triphosphate (ATP) [1]. Additionally, this molecule 
acts as the substrate for adenosine 3′,5′-cyclic monophosphate (cAMP) production, 
which is extensively used in intracellular signaling.
Although there was resistance to recognize the action of ATP in the extracel-
lular medium, nowadays, diverse mechanisms of cellular communication in living 
organisms have been considered as dependent on purinergic signaling. Numerous 
cell types released ATP autocrinally as a ubiquitous biologic and physiologic process 
[2]. A large number of purinergic receptors are activated for extracellular ATP and 
its metabolic breakdown acting on autocrine and paracrine manner [3, 4]. Thus, 
adenosine and other nucleotides activate the P1 and P2 receptors, respectively. 
P1 receptors are selective for adenosine, and P2 receptors are activated by purine 
and by pyrimidine nucleotides. Adenosine activates A1, A2A, A2B, and A3 receptors 
coupled to G-protein subtypes. Purines and pyrimidines may activate the P2Y 
receptors (eight subtypes in mammalian P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, 
and P2Y14) coupled to G-protein. P2X receptors are preferentially activated for 
purines (seven subtypes in mammalian P2X1, P2X2, P2X3, P2X4, P2X5, P2X6, P2X7) 
forming homotrimers and heterotrimers.
P1 and P2 receptors are abundant and widely distributed in all tissues of 
the body, mainly in mammals. In physiological conditions, they participate on 
neurotransmission, neuromodulation, sensory transduction, regulation of heart 
rate, smooth muscle contraction, bile secretion, endocrine regulation, immune 
responses, proliferation in development and regeneration, ischemia, and inflam-
mation [5].
2. Purinergic receptor participation in pathological conditions
The immune system uses pattern recognition receptors (PRRs) that recognize 
pathogen-associated molecular patterns (PAMPs) [6]. Besides pathogens, the 
immune system also reacts to particles that can cause damage-associated molecu-
lar patterns (DAMPs) [7], which are called hazard signaling molecules. Antigen 
presenters recognize them, once released or produced under stress conditions or 
cell death, which become activated and generate costimulatory signals and thus 
initiate immune responses and inflammation [8]. Different chemical agents are 
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capable of inducing the inflammatory response, even in the absence of infection. 
Sterile inflammation is marked by neutrophil and macrophage recruitment and for 
cytokine production such as TNF-α and IL-1β [9]. Nucleotides (ATP, UTP, or ADP) 
can act as DAMPS in the extracellular medium under stressful conditions and are 
released with other molecules out of the cell. In the environment, these nucleotides 
are recognized by a cell expressing purinergic receptors, including the antigen-pre-
senting cells (APCs). Thus, they serve as signaling molecules of danger to APCs. In 
this context, in an ATP cell release event injured, many classes of receptors (some-
times of different actions) are activated in effector cells and can generate a network 
of intracellular signaling cascades responsible for late effects [10]. Several studies in 
recent years have shown that purinergic signaling plays an essential regulatory role 
in many inflammatory diseases [11]. Additionally, these receptors may modulate 
diverse diseases such as chronic pain, brain trauma ischemia, epilepsy, Alzheimer 
disease, amyotrophic lateral sclerosis, depression, anxiety, schizophrenia throm-
bosis and stroke, dry eye, atherosclerosis, kidney failure, osteoporosis, bladder 
incontinence, colitis, neurodegenerative diseases, and cancer [12–14].
3. Purinergic receptor as therapeutic targets
Classically, in the function of ubiquitous purinergic receptor expression, the 
agonists and antagonists for these receptors exhibit a lack of drug selectivity and 
the possibility of side effect in vivo. However, the advance of medicinal chemistry 
area in the last decades has developed potent and selective synthetic agonists and 
antagonists for purinergic receptors. The boost of bioinformatic analysis with 
power tools allows studying purinergic receptors’ structure in details and discover-
ing, in some cases, allosteric modulators with therapeutic window better than 
orthosteric compounds [15–17].
Undoubtedly, purinergic receptors, P2X receptor, P2Y receptor, and ectonucleo-
tidase pharmacology is an attractive area for pharmacotherapeutic development 
and, therefore, provides a contemporary understanding of the purinergic signaling 
in physiological and pathological conditions. Additionally, this content will include 
of the relationship between purinergic receptors subtypes and ectonucleotidases at 
molecular, pharmacological, and therapeutic conditions.
We are grateful to all the authors for their valuable contribution and hope that 
this book could represent, for the scientific community, a solid basis for further 
studies on purinergic receptors.
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